Previous 10 | Next 10 |
Cogent Biosciences (COGT) has priced 10,256,411 common shares at $9.75/share, for gross proceeds of ~$100M (from $60M).Underwriters over-allotment is an additional 1,538,461 shares.Offering is expected to close on December 4. Net proceeds will be used for development, regulatory and commercia...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined di...
Gainers: [[NTN]] +20.7%. [[WDC]] +7.9%. [[NCNA]] +7.4%. [[SPCE]] +5.6%. [[JFIN]] +5.4%.Losers: [[MOHO]] -7.9%. [[COGT]] -6.7%. [[FOUR]] -6.7%. [[EMKR]] -6.6%. [[OBLG]] -6.6%. For further details see: NTN, NCNA, MOHO and EMKR among after-hours movers
Thinly traded micro cap Cogent Biosciences (COGT) is under modest pressure after hours in reaction to its $60M public offering of common stock. Price, volume and terms have yet to be announced.Shares down 7%. For further details see: Cogent Bio launches $60M equity offering, shares...
Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 30, 2020 CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on devel...
Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing PR Newswire CAMBRIDGE, Mass., Nov. 3...
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference PR Newswire CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company ...
Cogent Biosciences ([[COGT]] +1.2%) has announced final results from Phase 1/2 study evaluating combination of PLX9486 + Pfizer's Sutent (sunitinib) in patients with advanced gastrointestinal stromal tumors ((GIST)). Data will be presented at the Connective Tissue Oncology Soc...
Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020 Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavi...
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 12, 2020 CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focuse...
News, Short Squeeze, Breakout and More Instantly...
Cogent Biosciences Inc Com Company Name:
COGT Stock Symbol:
NASDAQ Market:
Cogent Biosciences Inc Com Website:
2024-07-06 14:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Admin...
2024-06-26 16:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...